In studies on patients with nasopharyngeal cancer, the spliced fibulin-2 isoform (FBLN2S) is expressed in adjacent normal tissues, is silenced in primary tumor tissues and nasopharyngeal cancer cell lines, is selectively re-expressed in cell lines following 5-azacytidine treatment, and exerts tumor suppressor activity when reintroduced into cells [20]. This evidence concerns the gene FBLN2 and nasopharyngeal carcinoma.